Literature DB >> 3516787

Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation.

J Rakela, S B Kurtz, J T McCarthy, J Ludwig, N L Ascher, J R Bloomer, P L Claus.   

Abstract

A 22-yr-old woman presented with fulminant Wilson's disease. The diagnosis was suspected clinically and was later confirmed with chemical and pathologic studies. She presented with acute hepatic failure, hemolysis, and acute anuric renal failure. Postdilution hemofiltration and continuous arteriovenous hemofiltration with oral D-penicillamine allowed removal of a total of 95,700 micrograms of copper; 78,665 micrograms of the total were removed via postdilution hemofiltration alone. On the 57th day, the patient received successful liver and renal transplants. We found that the determination of serum copper was instrumental in the diagnosis of fulminant Wilson's disease, that postdilution hemofiltration allowed a rapid removal of copper in the presence of renal failure, and that, finally, orthotopic liver transplantation should be performed early in the clinical course of these patients. This patient is the longest survivor of this serious condition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516787     DOI: 10.1016/0016-5085(86)90274-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine.

Authors:  F Durand; J Bernuau; E Giostra; G Mentha; D Shouval; C Degott; J P Benhamou; D Valla
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Copper metabolism after living related liver transplantation for Wilson's disease.

Authors:  Xue-Hao Wang; Feng Cheng; Feng Zhang; Xiang-Cheng Li; Jian-Ming Qian; Lian-Bao Kong; Hao Zhang; Guo-Qiang Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

3.  Orthotopic liver transplantation in liver-based metabolic disorders.

Authors:  A P Mowat
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

4.  Plasma exchange for fulminant Wilson disease.

Authors:  J Sarles; P Lefevre; G Picon
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

5.  Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests.

Authors:  Jessica D Korman; Irene Volenberg; Jody Balko; Joe Webster; Frank V Schiodt; Robert H Squires; Robert J Fontana; William M Lee; Michael L Schilsky
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

6.  D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson's disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson's disease.

Authors:  Isao Sakaida; Kotaro Kawaguchi; Teruaki Kimura; Fusako Tamura; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2005-06       Impact factor: 7.527

7.  Orthotopic liver transplantation for fulminant and subacute hepatic failure.

Authors:  A C Stieber; G Ambrosino; D Van Thiel; S Iwatsuki; T E Starzl
Journal:  Gastroenterol Clin North Am       Date:  1988-03       Impact factor: 3.806

8.  Orthotopic liver transplantation for fulminant and subacute hepatic failure.

Authors:  A C Stieber; S Iwatsuki; T E Starzl
Journal:  ASAIO Trans       Date:  1988 Oct-Dec

9.  Dietary supplement implicated in fulminant hepatic failure in a well-controlled Wilson disease patient.

Authors:  Kengo Kawai; Yoshinari Atarashi; Terumi Takahara; Hiroshi Kudo; Kazuto Tajiri; Yoshiharu Tokimitsu; Yasuhiro Nakayama; Katsuharu Hirano; Yutaka Yata; Masami Minemura; Satoshi Yasumura; Yasuharu Onishi; Kazuhiro Tsukada; Koichi Tsuneyama; Yasuo Takano; Toshiro Sugiyama
Journal:  Clin J Gastroenterol       Date:  2009-01-22

10.  Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure: first successful case report.

Authors:  G Gubernatis; R Pichlmayr; J Kemnitz; K Gratz
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.